Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

286 results about "Genes human" patented technology

The human genome is the complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria. Human genomes include both protein-coding DNA genes and noncoding DNA.

Method for diagnosing non-small cell lung cancers

Disclosed are methods for detecting, diagnosing, treating and preventing non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes, whose expression is elevated in non-small cell lung cancer compared to non-cancerous tissues, are provided. Also disclosed are agents for treating and preventing non-small cell lung cancer as well as methods for identifying further compounds for treating and preventing non-small cell lung cancer.
Owner:ONCOTHERAPY SCI INC

Mutations in human MLH1 and human MSH2 genes useful in diagnosing colorectal cancer

Variant human MLH1 and MSH2 genes are provided. Methods of using these variant genes to diagnose hereditary non-polyposis colorectal cancer (HNPCC) and / or determine a patient's susceptibility to developing HNPCC are also provided. Methods and compositions for identifying new variant MLH1 of MSH2 genes are also provided. In addition, experimental models for hereditary non-polyposis colorectal cancer comprising these variant genes are provided.
Owner:DIADEXUS

Packaging cell lines for generation of high titers of recombinant AAV vectors

AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and can negatively affect the host cell. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems and that allow for substantially increased packaging efficiency.
Owner:TARGETED GENETICS CORPORTION

Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)

A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
Owner:AMGEN INC

Coagulation factor x polypeptides with modified activation properties

The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.
Owner:CSL BEHRING GMBH

Genemap of the human genes associated with longevity

InactiveUS20090305900A1Electrolysis componentsVolume/mass flow measurementGenomicsLinkage Disequilibrium Mapping
The present invention relates to the selection of a set of SNP markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's longevity, their protection against age-related diseases and / or their response to a particular drug or drugs.
Owner:BELOUCHI ABDELMAJID +12

Genemap of the human genes associated with crohn's disease

InactiveUS20090081658A1Reduce frequencyTreatment safetyMicrobiological testing/measurementGenomicsLinkage Disequilibrium Mapping
The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life

The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and / or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
Owner:CSL BEHRING GMBH

Primers, probes, kit and method for detecting human EGFR (epidermal growth factor receptor) gene mutations

The invention provides primers, probes, kit and method for detecting human EGFR (epidermal growth factor receptor) gene mutations. The method comprises the following steps of: (1) providing the primers and the probes; (2) processing detected samples and extracting DNA (deoxyribonucleic acid); (3) carrying out fluorescent quantitation on components of a PCR (polymerase chain reaction) system; (4) amplifying target sequences of an EGFR gene mutation to be detected; and (5) distinguishing wild type genes and mutant type genes by utilizing ARMS (amplification refractory mutation system) primers and judging results via the fluorescence intensity of an FAM and a JOE. The primers, probes and method provided by the invention have the beneficial effects that 29 kinds of mutations on the EGFR genes can be simultaneously detected, so that the sensitivity is high, the specificity is strong and the detection speed is high; and the whole detection process only takes 60 minutes.
Owner:武汉海吉力生物科技有限公司

Genemap of the human genes associated with psoriasis

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to psoriasis disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Method for detecting the risk of and for treatment of type 2 diabetes

A role of the human EXT2 gene in metabolic conditions such as T2D is disclosed. Methods and test kits for diagnosis, T2D risk prediction and prediction of clinical course of a metabolic condition using biomarkers related to the EXT2 gene are disclosed. Novel methods for prevention and treatment of metabolic diseases based on EXT2 gene, polypeptides and EXT2 related pathways are also disclosed.
Owner:JURILAB

Genemap of the human genes associated with adhd

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to ADHD disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Human idiopathic basal ganglia calcification disease-causing gene and coding protein thereof

The invention provides a variant human SLC20A2 gene and discloses that the variant human SLC20A2 gene is idiopathic basal ganglia calcification disease-causing gene. By utilizing the variant human SLC20A2 gene, diagnosis and risk evaluation can be carried out on idiopathic basal ganglia calcification disease. The invention also provides a protein coded by the variant human SLC20A2 gene, and the protein can be taken as a drug target for treating basal ganglia calcification. Besides, the invention also provides a kit used for diagnosing the idiopathic basal ganglia calcification disease and an application of the variant human SLC20A2 gene in preparation of a human idiopathic basal ganglia calcification disease gene diagnosis chip.
Owner:WUHAN TOAZHI LIFE TECH

Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene

The disclosure relates to oligomers capable of targeting RNA expressed from the human C9ORF72 gene containing a pathogenic hexanucleotide repeat expansion. Such oligomers are useful for, among other things, reducing or eliminating C9ORF72 RNA and / or proteins translated therefrom, and treating or preventing diseases or disorders caused by, or associated with, hexanucleotide repeat expansion, including familial frontotemporal dementia (FTD) and familial amyotrophic lateral sclerosis (ALS).
Owner:PFIZER INC

Genemap of the human genes associated with crohn's disease

The present invention relates to the selection of a set of polymorphism makers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (ex: Chrohn's disease) and / or their response to a particular drug or drugs.
Owner:BELOUCHI ABDELMAJID +12

Nucleic acids encoding tumor necrosis factor receptor 5

The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5", and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
Owner:HUMAN GENOME SCI INC

Modified Coagulation Factor VIIa With Extended Half-Life

The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
Owner:CSL BEHRING GMBH

Genemap of the human genes associated with crohn's disease

InactiveUS20100081129A1Genetic material ingredientsMicrobiological testing/measurementLinkage Disequilibrium MappingPharmacogenomic Study
The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and / or their response to a particular drug or drugs.
Owner:GENIZON BIOSCI

Novel sequences and their use

Novel non-coding sequences isolated upstream of the human IRS-2 gene are disclosed as markers for the prediction and / or diagnosis of IRS-2 related metabolic disorders or diseases, such as diabetes. The sequences also fiction as markers in a method and assay for evaluating the insulin regulating, i.e. insulin sensitizing or inhibiting properties of drug candidate substances, e.g. a method and assay for high throughput screening. The sequences and / or information derived therefrom can also be used for influencing the expression of the IRS-2 gene, e.g. in the therapy of IRS-2 related metabolic disorders, such as diabetes.
Owner:METCON MEDICIN

Genes and polypeptides relating to breast cancers

The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK / TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.
Owner:ONCOTHERAPY SCI INC

Packaging cell lines for generation of high titers of recombinant AAV vectors

AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and can negatively affect the host cell. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems and that allow for substantially increased packaging efficiency.
Owner:TARGETED GENETICS CORPORTION

Diagnosis and treatment methods related to aging, especially of liver

Mouse genes differentially expressed in comparisons of older and younger livers by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against faster-than-normal biological aging, or to achieve slower-than-normal biological aging. The human molecules may also be used as markers of biological aging.
Owner:OHIO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products